Last reviewed · How we verify
Gentamicin - single dose
At a glance
| Generic name | Gentamicin - single dose |
|---|---|
| Sponsor | Murdoch Childrens Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic (NA)
- Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis (PHASE2)
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial (PHASE4)
- Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children (PHASE4)
- TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden (PHASE3)
- Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections (PHASE2)
- Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery (PHASE3)
- Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gentamicin - single dose CI brief — competitive landscape report
- Gentamicin - single dose updates RSS · CI watch RSS
- Murdoch Childrens Research Institute portfolio CI